HealthModerna-Merck combination succeeds in late-stage skin cancer trial
Moderna and Merck said a combination of Moderna’s mRNA vaccine and Merck’s Keytruda immunotherapy succeeded in a late-stage skin cancer trial, sending Moderna shares up 60% in premarket trading.
C
CNN★★★☆☆2026-08-19 12:30Original
Moderna-Merck combination succeeds in late-stage skin cancer trial